iShares U.S. Pharmaceuticals ETF IHE

iShares U.S. Pharmaceuticals ETF, anteriormente conocido como iShares Dow Jones U.S. Pharmaceuticals Index Fund (el Fondo), es un fondo cotizado en bolsa. El Fondo busca obtener resultados de inversión que se correspondan generalmente con el rendimiento del precio y el rendimiento por dividendos del Dow Jones U.S. Select Pharmaceuticals Index (el Índice). El Índice mide el rendimiento del sector farmacéutico del mercado de valores de Estados Unidos e incluye empresas farmacéuticas como fabricantes de medicamentos recetados o de venta libre o vacunas, pero excluye a los productores de vitaminas. El Fondo invierte en una muestra representativa de valores incluidos en el Índice que en conjunto tienen un perfil de inversión similar al Índice. Debido al uso de muestreo representativo, el Fondo puede o no tener todas las acciones que están incluidas en el Índice. El asesor de inversión del Fondo es BlackRock Fund Advisors.

Con 10 acciones de IHE (USD 985,08) habrías recibido USD 14,30 en dividendos en los últimos 12 meses.

IHE hizo una división de acciones (split) de 3:1 el 7 de marzo de 2024: cada acción se convirtió en 3. Cambió la cantidad de acciones y su precio, pero no el valor total de la inversión.

• Zacks Investment Research 15 sept

  Should You Invest in the iShares U.S. Pharmaceuticals ETF (IHE)?

  The iShares U.S. Pharmaceuticals ETF (IHE) is a passively managed fund offering broad exposure to the Healthcare-Pharma sector with $1.63 billion in assets. The ETF has delivered strong year-to-date returns of 20.69% and 45.67% over the past year, though it carries higher risk with a beta of 0.49 and standard deviation of 16.8%. It holds approximately 60 pharmaceutical companies with top holdings including Johnson & Johnson (22.21%), Eli Lilly, and Bristol Myers Squibb, and carries a Zacks ETF Rank of 3 (Hold).

  

• The Motley Fool 8 sept

  Is the iShares Pharmaceuticals ETF or iShares Healthcare ETF the Better Fund for 2026?

  The article compares two healthcare-focused ETFs from iShares: IHE (Pharmaceuticals ETF) with 55 holdings and IYH (Healthcare ETF) with 100 holdings. While IHE delivered stronger 1-year returns of 50% versus IYH's 27.4%, the article recommends IYH as the better choice due to superior 3- and 5-year performance, greater diversification, and larger asset base of $3.9B. Both funds have identical 0.37% expense ratios.

  

• The Motley Fool 14 ago

  Fidelity Healthcare ETF vs. iShares Pharma Fund: Which Wins?

  Fidelity MSCI Health Care Index ETF (FHLC) and iShares U.S. Pharmaceuticals ETF (IHE) offer different approaches to healthcare investing. FHLC provides broad diversification across 338 healthcare holdings with a lower 0.08% expense ratio, while IHE focuses on 56 pharmaceutical stocks with higher concentration risk but delivered 60% one-year returns. The analysis recommends FHLC for its superior diversification and lower costs, despite IHE's recent outperformance.

  

• The Motley Fool 22 jul

  Which ETF Is Healthier for Your Portfolio: Vanguard Health Care ETF or iShares Pharmaceuticals ETF?

  The article compares two healthcare-focused ETFs: Vanguard Health Care ETF (VHT) and iShares U.S. Pharmaceuticals ETF (IHE). VHT offers broader diversification with 411 holdings and a lower 0.09% expense ratio, while IHE provides concentrated pharmaceutical exposure with 56 holdings and has delivered superior 5-year returns (11.8% vs 5.4%). The author recommends IHE as the better buy for 2026 due to stronger recent performance and lower maximum drawdown, despite VHT's cost advantages.

  

• The Motley Fool 18 jul

  IHE vs IXJ: Which Popular Healthcare ETF Is the Better Buy for Investors?

  The article compares two healthcare ETFs: IHE (U.S. Pharmaceuticals) and IXJ (Global Healthcare). IHE offers concentrated exposure to 56 U.S. pharmaceutical companies with higher recent returns (50.30% 1-yr), but carries significant concentration risk with its top two holdings (J&J and Eli Lilly) comprising 43% of the portfolio. IXJ provides broader diversification across 110 international healthcare companies including medical devices and services, with lower concentration risk but more modest recent returns (18.20% 1-yr). The article suggests IXJ is better for diversification-focused investors, while IHE's outperformance is largely driven by GLP-1 weight-loss drug success.